Arcus Biosciences Inc. (NYSE:RCUS) Relative Strength Index (RSI) is 31.01, with weekly volatility at 4.32% and ATR at 1.18. The RCUS stock’s 52-week price range has touched low of $16.69 and a $42.36 high. Intraday shares traded counted 0.61 million, which was -17.71% lower than its 30-day average trading volume of 519.38K. Its shares traded lower over the last trading session, losing -0.96% on 06/17/21. The shares fell to a low of $23.285 before closing at $23.77. RCUS’s previous close was $24.00 while the outstanding shares total 67.08M.
Investors have identified the Biotechnology company Arcus Biosciences Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.69 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Arcus Biosciences Inc. (RCUS) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 841.87 million total, with 132.06 million as their total liabilities.
RCUS were able to record -69.96 million as free cash flow during the 08/11/2021 quarter of the year, this saw their quarterly net cash flow reduce by 218.63 million. In cash movements, the company had a total of -66.32 million as operating cash flow.
Potential earnings growth for Arcus Biosciences Inc. (RCUS)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/11/2021 quarter of the year, Arcus Biosciences Inc. recorded a total of 9.46 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 81.5% coming in sequential stages and their sales for the 08/11/2021 quarter reducing by -0.27%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 9.46 million trying to sell their products during the last quarter, with the result yielding a gross income of 82.21 million. This allows shareholders to hold on to 67.08M with the recently reported earning now reading -1.08 cents per share. This is a figure that compared to analyst’s prediction for their 08/11/2021 (-1.08 cents a share).
Having a look at the company’s valuation, the company is expected to record -3.69 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on RCUS sounds very interesting.
Is the stock of RCUS attractive?
In related news, Chief Operating Officer, Jarrett Jennifer sold 1,044 shares of the company’s stock in a transaction that recorded on Jun 04. The sale was performed at an average price of 24.91, for a total value of 26,006. As the sale deal closes, the Director, KANEKO YASUNORI now bought 4,133 shares of the company’s stock, valued at 129,652. Also, Chief Medical Officer, Grossman William sold 4,133 shares of the company’s stock in a deal that was recorded on Apr 23. The shares were price at an average price of 31.37 per share, with a total market value of 129,652. Following this completion of acquisition, the Director, FALBERG KATHRYN E now holds 20,000 shares of the company’s stock, valued at 566,996. In the last 6 months, insiders have changed their ownership in shares of company stock by 20.60%.